Sun Life (SLF) Q4 2025 earnings review
Insurance Operations Shine, MFS Bleeds
Sun Life closed FY25 with a resounding beat, delivering Underlying EPS of $1.96 (+17% YoY) and an impressive 19.1% ROE. The narrative of 'diversification' worked perfectly: while MFS suffered massive $25.4B outflows, the insurance pillars did the heavy lifting. Asia sales exploded (+49%), Canada Wealth surged (+46%), and the troubled U.S. medical stop-loss business finally reversed its negative morbidity trend. While the 12% annual EPS growth hits the bullseye of their medium-term objective, the sheer velocity of asset flight at MFS remains a critical structural concern.
🐂 Bull Case
After quarters of dragging earnings down due to high claims severity, U.S. Group Health & Protection Underlying NI jumped 16% YoY. Management explicitly cited 'improved medical stop-loss morbidity experience,' confirming that aggressive repricing actions taken in early 2025 are finally sticking.
Asia is not just growing; it is accelerating. Individual sales skyrocketed 49% YoY (vs. +12% in Q4'24), driven by Hong Kong and India. This high-margin growth engine is operating at full throttle.
🐻 Bear Case
MFS saw net outflows of $25.4 billion in a single quarter—worsening significantly from Q3'25 ($1.2B) and Q4'24 ($28.5B). While markets lifted AUM, the organic decay in this fee-generating engine is alarming.
Corporate expenses and other net loss widened to $110M (vs $97M prior year), driven by higher financing costs. As the company levers up to buy out SLC affiliates, this drag on the bottom line is increasing.
⚖️ Verdict: 🟢
Bullish. The core insurance businesses (Canada, Asia, U.S.) are firing on all cylinders, effectively masking the weakness in traditional asset management. The fix in U.S. morbidity is a major catalyst removed from the risk column.
Key Themes
Asset Management Divergence: SLC Wins, MFS Loses
A stark dichotomy exists within the Asset Management pillar. SLC Management (Alternatives) continues to attract capital with $5.9B in net inflows. In contrast, MFS (Traditional) hemorrhaged $25.4B in outflows due to retail equity weakness and institutional rebalancing. While total AUM is up due to markets, the organic growth story is entirely dependent on SLC.
Asia Sales Explosion
Accelerating. Asia individual protection sales growth hit +49% YoY, a massive acceleration from the +12% seen a year ago. Gains were broad-based (Hong Kong, India, Indonesia). Importantly, New Business CSM (Contractual Service Margin)—a predictor of future profit—rose 20% YoY globally, primarily driven by this Asian volume.
Canada Wealth Resurgence
Accelerating. Canada Asset Management & Wealth sales surged 46% YoY to $7.2B. This was driven by Group Retirement Services (GRS) and Individual Wealth mutual funds. After quarters of sluggishness due to rate uncertainty, the Canadian wealth machine is back online.
U.S. Distribution Cost Headwinds
Stable/Persisting. While the morbidity issue in the U.S. has improved, management flagged 'higher distribution costs' in U.S. Group Benefits as a partial offset to gains. This suggests Sun Life may be paying more to brokers/partners to retain or win business in a competitive repricing environment.
Asset Management Restructure
Sun Life is formally restructuring. Effective Jan 1, 2026, a new 'Sun Life Asset Management' pillar will combine MFS, SLC, and the Asian asset management stakes. This move is designed to force synergies between the disconnected private (SLC) and public (MFS) arms, potentially signaling future cost actions or product integrations.
Financing Costs Weighing on Corporate
Decelerating. The Corporate segment loss widened to $110M. Management explicitly attributed the $13M YoY worsening to 'higher financing costs supporting the acquisition of our remaining interests in SLC Management affiliates.' As SLF buys out the remaining stakes in BGO and Crescent, debt service is eating into the bottom line.
Other KPIs
Accelerating. Up significantly from 16.5% in 24Q4. This is a standout metric, well above the 18% medium-term objective, demonstrating high capital efficiency despite the MFS drag.
Stable/Strong. Increased from 152% a year ago and 154% in Q3. This massive capital buffer allows for the 4.5% dividend hike and continued buybacks (4.7M shares repurchased in Q4).
Accelerating. Sales grew 45% YoY (vs a -9% decline in 24Q4). This confirms that despite aggressive repricing to fix margins, the franchise remains competitive and is winning large mandates.
Guidance
Stable. The company does not provide quarterly guidance but measures itself against medium-term objectives. Delivering 12% growth in FY25 validates the target. Given the momentum in Asia and U.S. recovery, this target looks durable for FY26.
Stable. Within the target range of 40-50%. The dividend was increased by $0.04 to $0.92 per share starting Q4.
Negative. This has been a recurring 'one-time' drag. In Q4, results were impacted by $49M lower-than-expected tax-exempt income. While better than the $234M hit in 24Q4, it remains a volatility factor in the Corporate segment.
Key Questions
MFS Flow Reversal Timeline
MFS outflows accelerated to $25.4B this quarter despite a bull market. Is this purely industry beta (active vs passive), or are there specific mandate losses? What is the path to positive flows in FY26?
Sustainability of U.S. Margins
U.S. margins recovered due to improved morbidity. Was there any favorable reserve release (catch-up) in Q4 that flatters this number, or is this the true run-rate profitability post-repricing?
SLC Buyout Impact
Corporate losses are widening due to financing costs for the SLC affiliate buyouts. When does the earnings accretion from owning 100% of these affiliates cross over the debt service costs?
Asia Pricing Competition
While Asia sales are up 49%, margins in Hong Kong 'reduced from prior year.' Are we trading margin for volume to capture market share in the region?